ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 802

Sensorineural Hearing Loss in Takayasu’s Arteritis

Ugur Kimyon1, Sinem Nihal Esatoglu1, Ebru Kara2, Ahmet Atas2, Elif Emel Gunay2, Emine Deniz Gozen2, Emin Karaman2, Vedat Hamuryudan1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: observation, systemic lupus erythematosus (SLE) and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sensorineural hearing loss has been reported to be increased in several chronic autoimmune and non-autoimmune diseases such as systemic lupus erythematosus (SLE), progressive systemic sclerosis, rheumatoid arthritis, small vessel vasculitides, ankylosing spondylitis and Behçet’s syndrome. We had sporadically noted several degrees of sensorineural hearing loss among our Takayasu’s arteritis (TA) patients. While, some revealed this in their past history, others had relapsing attacks of hearing loss independent of or associated with vascular relapses. We formally investigated the frequency and type of hearing loss among TA patients and suitable controls.  

Methods: The study was done in two parts. In the first part, consecutive TA and SLE patients seen at outpatient clinic along with apparently healthy controls were administered a standardized questionnaire that assessed hearing loss, tinnitus and episodic vertigo. In the second part previously registered TA and SLE patients for another study (1-2), were called to specifically for otological examination and audiometry tests that included pure-tone air and bone   conduction, speech audiometry and acoustic reflex threshold test.

Results: In the first part, 73 patients with TA, 107 patients with SLE and 133 healthy controls were studied as shown in Table 1. The frequency of those with hearing deficit/loss, tinnitus and vertigo were significantly more common among both TA and SLE patients (Table 1). While the frequency of those with hearing deficit/loss was similar in TA and SLE, those with tinnitus and vertigo were significantly most common in TA.

Audiometry tests revealed that, several degrees of hearing loss were present in 36.6 % of the patients with TA and 25.0 % of the patients with SLE (Table 2). This was mostly due to sensorineural hearing loss in both groups (TA: 31.7 %; SLE: 20.0 %) and high –frequency type was the most common pattern. Moreover, those TA patients with sensorineural hearing loss did not show any specific vascular pattern.

Conclusion: We are unaware of previous surveys of sensorineural hearing loss in TA. Our study shows that audiovestibular system is considerably affected in TA, similar to that observed in SLE. The fact that there was no clear vascular pattern among patients with hearing loss, suggest that small vessel vasculitis was probably the cause of this hearing loss.

     

 

Table 1. Results of the questionnaire survey

 

 

Takayasu’s arteritis

(n = 73)

SLE

(n = 107)

Healthy controls

(n= 133)

 

p value

Mean age

43.7 ± 11.0

44.0 ± 10.3

42.5 ± 8.3

NS

Disease duration, med [IQR]

7 [3-12]

8 [3-11]

NA

NS

Hearing deficit/loss, n (%)

20 (27.4)

21 (19.6)

4 (3.0)

0.001

Tinnitus, n (%)

37 (50.7)

34 (31.8)

16 (12.0)

0.001

Vertigo, n (%)

39 (53.4)

38 (35.5)

19 (14.3)

0.001

 

Table 2. Results of the audiometry tests

 

 

Takayasu’s arteritis,

(n = 41)

SLE

(n = 20)

p value

Mean age

41.3 ± 8.9

42.1 ± 10.3

NS

Disease duration, med [IQR]

6 [4-11]

7 [3-11]

NS

Hearing loss, n (%)

15 (36.6)

5 (25.0)

NS

     Sensorineural type, n (%)

12 (29.3)

4 (20.0)

 

     Conductive type, n (%)

3 (7.3)

1 (5.0)

 

 


Disclosure: U. Kimyon, None; S. N. Esatoglu, None; E. Kara, None; A. Atas, None; E. E. Gunay, None; E. D. Gozen, None; E. Karaman, None; V. Hamuryudan, None; H. Yazici, None; E. Seyahi, None.

To cite this abstract in AMA style:

Kimyon U, Esatoglu SN, Kara E, Atas A, Gunay EE, Gozen ED, Karaman E, Hamuryudan V, Yazici H, Seyahi E. Sensorineural Hearing Loss in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/sensorineural-hearing-loss-in-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sensorineural-hearing-loss-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology